Articles tagged with Tuberculosis
Healthcare personnel working in poorly ventilated general hospital rooms were at risk for sero-conversion of tuberculosis. Improving ventilation to at least two air exchanges per hour can help prevent this risk. Additionally, a program using an educational videotape and brochure increased colon cancer screening rates among patients.
A study analyzing Ontario data found that immigration officials' referrals and region of origin are key determinants of tuberculosis risk. Immigrants from Vietnam had the highest incidence rate, emphasizing the importance of targeted prevention efforts to protect both migrant populations and native Canadians.
The NIAID Challenge Grants program will award $19 million to eight companies to develop new drugs and vaccines against deadly infectious diseases. Researchers will work on developing a pediatric indication for tafenoquine to prevent malaria in adults, as well as studying azithromycin for treating malaria.
The Sequella Global Tuberculosis Foundation invites researchers worldwide to apply for $50,000 grants to develop effective vaccines for human tuberculosis. The program aims to spur innovation and encourage new approaches to vaccine development.
Researchers discovered an enzyme called isocitrate lyase (ICL) that allows TB bacteria to persist in macrophages and evade immune attack. A drug targeting ICL may reduce treatment time for chronic infection. The enzyme's crystal structure has been determined, providing clues for designing drugs to attack persistent TB bacteria.
A consortium of researchers found that isocitrate lyase (ICL) enables the tuberculosis bacterium to use fatty acids as energy. Disabling ICL crippled the bacterium in its persistent phase, suggesting a potential target for TB therapies. Current treatments are often ineffective due to the bug's ability to persist in the body.
Researchers found 46% of Peruvian plant extracts inhibited Mycobacterium tuberculosis, the TB bacterium. This discovery could lead to developing new pharmaceuticals to combat the disease.
A recent study published in The American Journal of Human Genetics has found a major genetic component to TB susceptibility, specifically in a group of aboriginal Canadians. Individuals with at least one high-risk copy of the NRAMP1 gene are ten times more likely to develop TB than those without it.
The Blueprint for TB Vaccine Development identifies the TB crisis as a global health priority and encourages an international collaborative effort to develop a vaccine. The report details three different vaccine concepts currently being developed: live, attenuated vaccines; subunit vaccines; and naked DNA vaccines.
A new TB drug candidate, PA-824, has been shown to be effective against MDR strains of the bacteria. The compound, developed by PathoGenesis Corporation with assistance from NIAID's Laboratory of Host Defenses, works by preventing MTB from forming an important fatty acid component of its cell walls.
Susan Okie, a medical reporter at The Washington Post, has won the 2000 American Society for Microbiology (ASM) Public Communications Award. Her two-part series on tuberculosis highlights the challenges of controlling this deadly disease and emphasizes the need for new medicines and vaccines to eradicate it.
Researchers have created a mutant strain of Mycobacterium tuberculosis that fails to establish a lethal chronic infection in mice. Targeting the pcaA gene, which codes for an enzyme essential for virulence, may lead to breakthroughs in TB treatment.
Researchers found that treated sleep apnea patients experienced no auto accidents over two years. A new biochemical marker for acute lung injury has been discovered, correlating with damage to epithelial cells in the lungs. This discovery may lead to future blood tests for the deadly condition.
A new rapid and reliable method for detecting tuberculosis has been developed, using the microscopic observation broth-drug susceptibility assay (MODS). The test is inexpensive and sensitive enough to be used in the field by health officers in developing countries.
The Tuberculosis Research Unit at CWRU will work with seven basic science sites and three clinical sites to evaluate new drugs, vaccines, and diagnostic tests. The unit aims to alleviate the burden of TB, which affects 1.7 billion people worldwide.
Researchers at Johns Hopkins Medicine reported a groundbreaking case of tuberculosis transmission from a cadaver to an embalmer, revealing the first documented instance of such a transmission. The study emphasizes the need for updated guidelines and precautions to prevent similar incidents in funeral homes.
Two groups of researchers at Colorado State University will receive funding to develop new drugs against tuberculosis, a leading bacterial killer causing 10 million new cases annually. The research teams will collaborate with pharmaceutical companies and use advanced testing infrastructure to identify potential anti-TB compounds.
Researchers from the Howard Hughes Medical Institute identified a crucial lipid molecule produced by M. tuberculosis to infect lung tissue. The discovery could lead to improved vaccines and treatments for tuberculosis, which kills more people than AIDS or malaria.
The report highlights the rapid spread of multidrug-resistant tuberculosis (MDR-TB) to Western Europe and North America, reaching unprecedented levels in over 100 countries. Immediate implementation of the World Health Organization's DOTS program and new resources are urgently needed to combat the growing epidemic.
A study found that TB was transmitted among inmates and guards in a city jail, highlighting the need for aggressive TB detection and treatment. Meanwhile, a qualitative study identified five components of successful work with victims of domestic violence and emphasized the importance of 'compassionate asking' to address this complex so...
Researchers at UCSF have discovered how Mycobacterium tuberculosis outsmarts the immune system to cause disease. The microbe disrupts a protein called STAT1, blocking macrophages' ability to respond to interferon gamma, allowing it to survive and infect other cells.
Researchers have identified 15 M. tuberculosis genes expressed only when the bacteria are growing in macrophages, key disease-fighting cells. These genes play important roles in pathogen metabolism, propagation and self-protection, potentially leading to new drug targets or vaccines.
Researchers have identified a substance produced by the tuberculosis bacterium that triggers an immune response, suggesting it could enhance vaccine effectiveness. The substance, combined with vaccines, may push the body's immune system in the right direction to fight tuberculosis and other microbial infections.
A new study by UCSF researchers found a significant decline in TB rates in San Francisco from 1992 to 1997, attributing it to intensified control measures. The study used molecular epidemiology to track the disease and determine the effect of interventions on transmission rates.
A new report by Johns Hopkins Medicine highlights the inadequate tuberculosis control programs in developing countries, particularly in sub-Saharan Africa where HIV infection rates are high. The report recommends improved screening, treatment, and integration of TB and HIV care to reduce transmission.
A new study suggests that crowded urban buses in Buenos Aires could be responsible for 30% of new tuberculosis cases. Researchers found that bus travel increases the risk of infection due to overcrowding and poor ventilation, posing a significant public health threat.
Researchers developed a code using first two letters of last name, first name, month of birth, year of birth, and sex. This allowed them to identify 124 HMO members with active TB listed in the state's registry but not known by their HMO
The development of a new vaccine is crucial to effectively eliminate tuberculosis (TB) as a global health problem. The ideal vaccine should prevent new infection, protect those already infected from developing active disease, and prevent reinfection in previously infected individuals.
Scientists have identified KasA, a critical protein in bacterial growth, as the target of isoniazid. This discovery enables the development of new anti-TB drugs and fast-screening assays to combat antibiotic-resistant strains.
Scientists have developed a new TB vaccine candidate that uses recombinant BCG strains to secrete pore-forming listeriolysin, improving its ability to stimulate CD8 T cells. This could lead to better protection against M. tuberculosis infection and potentially halve the estimated 2050 global TB cases.
A simplified regimen of twice-weekly isoniazid preventive therapy for six months or rifampicin and pyrazinamide for two months was found to be effective in preventing active tuberculosis in HIV-infected individuals. Higher compliance with treatment was observed among those who received the shorter course of treatment.
A two-month course of therapy is an effective alternative to the year-long regimen for preventing active tuberculosis in HIV-infected individuals. The study found that fewer deaths occurred among patients in the two-drug arm, with improved treatment compliance compared to the one-drug arm.
Researchers found that using rapid diagnostic methods for M. tuberculosis can decrease diagnosis time from 38.5 to 23 days, time to therapy from 6.6 to 2.0 days, and mortality by 22-33%. This also reduces healthcare costs per patient.
Researchers discovered identical DNA fingerprints in bacterial cultures from two TB patients who were bronchoscoped at the same hospital. The study emphasizes the importance of maintaining TB DNA fingerprint registries to identify unsuspected transmission modes.
Researchers have created an efficient method to study Mycobacterium tuberculosis (TB) using transposon mutagenesis, allowing them to examine the effect of individual gene mutations on the bacteria's ability to grow or cause disease. This breakthrough enables the development of new drug targets and potential vaccine candidates.
Tuberculosis bacteria use the C2a protein to lure macrophages to their death, a strategy that makes them effective pathogens. Understanding this mechanism may lead to the development of a novel vaccine to prevent tuberculosis.
Researchers found that HIV-positive patients living in the eastern United States are at a higher risk of developing tuberculosis, particularly if they have low levels of CD4 cells. The study also revealed that nearly 25% of those diagnosed with TB died from the disease.
Researchers at Johns Hopkins have found that spending more time and money on strict drug regimens saves money in the long run. The cost-effective strategy, called directly observed therapy (DOT), cures more people sooner and decreases the risk of developing TB germs resistant to treatment.